INMB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
INmune Bio Inc (INMB) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite the recent analyst upgrade and potential pipeline developments, the company's financial performance, technical indicators, and options data suggest caution. The stock lacks clear positive momentum, and there are no significant trading signals or catalysts to justify immediate investment.
The technical indicators are mixed. The MACD is slightly positive, indicating minor bullish momentum, but the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 1.188, with resistance at 1.265 and support at 1.112. Overall, the technical setup does not suggest a strong entry point.
Lucid Capital recently upgraded the stock to Buy with a price target increase from $2 to $9, citing the expanded scope of value drivers in the company's pipeline, particularly the CORDStrom therapy.
The company reported a significant net loss of $45.9 million for FY 2025, with a GAAP EPS of -$1.86, missing expectations. Revenue growth remains negligible despite a 400% YoY increase. Additionally, the stock has a high probability of declining in the short term based on historical patterns.
For Q4 2025, revenue remained flat at $0, while net income dropped by 42.89% YoY to -$5.26 million. EPS also declined by 51.22% YoY to -$0.2. While gross margin is 100%, the financials indicate poor profitability and growth.
Lucid Capital upgraded the stock to Buy from Neutral on March 11, 2026, with a price target increase from $2 to $9. This reflects optimism about the company's pipeline but does not align with the current financial and market performance.
